



Molecular Pathology of Lung Cancer: Current Status and Future Directions

Mee Sook Roh, M.D., Ph.D.

Department of Pathology, Dong-A University College of Medicine, Busan, Korea

The rapid development of targeted therapies has enormously changed the clinical management of lung cancer patients over the past decade; therefore, molecular testing, such as epidermal growth factor receptor (*EGFR*) gene mutations or anaplastic lymphoma kinase (*ALK*) gene rearrangements, is now routinely used to predict the therapeutic responses in lung cancer patients. Moreover, as technology and knowledge supporting molecular testing is rapidly evolving, the landscape of targetable genomic alterations in lung cancer is expanding as well. This article will summarize the current state of the most commonly altered and most clinically relevant genes in lung cancer along with a brief review of potential future developments in molecular testing of lung cancer.

Keywords: Lung Neoplasms; Biological Markers; Molecular Diagnostic Techniques

Introduction

Cancer is a disease of the cellular genome, and therefore lung cancers are understandably characterized by abundant genetic diversity. Information about genetic alterations and protein expression level is considered alongside histology in order to better comprehend the pathogenesis of lung cancer¹. Recent advances in the field of molecular-based cancer biology revealed that approximately 60% of adenocarcinomas and 20% of squamous cell carcinomas have an identified gene signature, and a finding that has led to the successful development and approval of targeted therapies². The use of targeted agents in lung cancer patients harboring epidermal growth

factor receptor (*EGFR*) gene mutations or anaplastic lymphoma kinase (*ALK*) gene rearrangements has been associated with dramatic response rates and improved progression-free survival (PFS)³⁻⁷, therefore, molecular testing is now routinely used to guide clinical care of lung cancer patients to predict one's therapeutic response¹.

Moreover, as the technology and knowledge supporting molecular testing is rapidly evolving, the landscape of targetable genomic alterations in lung cancer is expanding^{2,8-11}. However, the challenge of identifying biologically relevant driver mutations from the vast majority of passenger mutations remains.

To date, introduction of next-generation sequencing (NGS) technology offers the ability to detect high-throughput, multiple genetic alterations in both constitutional and cancer genomes¹². Such modern, but costly, technologies have not only contributed to our understanding of lung cancer biology, but have also provided the impetus for technical advances that may improve our ability to accurately discover the cancer genome^{13,14}.

This article will summarize the current state of the most commonly altered and most clinically relevant genes in lung cancer and potential future developments in molecular testing of lung cancer will be briefly reviewed.

Address for correspondence: Mee Sook Roh, M.D., Ph.D.

Department of Pathology, Dong-A University College of Medicine, 32 Daesingongwon-ro, Seo-gu, Busan 602-714, Korea

Phone: 82-51-240-2833, **Fax:** 82-51-243-7396

E-mail: msroh@dau.ac.kr

Received: Jun. 21, 2014

Revised: Jun. 27, 2014

Accepted: Jul. 4, 2014

©It is identical to the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>).

Copyright © 2014

The Korean Academy of Tuberculosis and Respiratory Diseases.

All rights reserved.

Current Status

1. Novel molecular targets

Although *EGFR* mutations and *ALK* fusions are well-characterized molecular targets in non-small cell lung cancer (NSCLC), activating alterations in a variety of potential oncogenic driver genes have also been identified in NSCLC. Table 1 summarizes a variety of genes involved in targeted treatment of NSCLC along with their respective histologic subtypes and the method of detection. However, it is important to recognize that not all potentially targetable biomarkers have been standardized outside of clinical trials. A deeper understanding of the molecular alteration of lung cancer may ultimately lead to personalized treatment strategies, which will improve care for those patients most likely to benefit, and spare the cost and morbidity associated with failed treatment interventions.

1) EGFR: *EGFR* encodes a transmembrane tyrosine kinase with an extracellular ligand-binding domain and an intracellular tyrosine kinase domain¹⁵. Activating somatic mutations are present in exons 18–21 of the tyrosine-kinase domain and deletions in exon 19 and the L858R point mutation in exon 21 occur in 90% of all *EGFR* mutations. They are associated with a response rate of approximately 70% to EGFR-tyrosine kinase inhibitor (TKI) therapy¹⁶. *EGFR* mutations are primarily seen in adenocarcinoma. Therefore, *EGFR* mutation analysis is the best predictive marker for the use of EGFR-TKI therapy in NSCLC with an adenocarcinoma component, but gender, ethnicity, and smoking status are unsuitable for use as triage

for mutation analysis. The most common mechanism of resistance to EGFR-TKI is the T790M gatekeeper mutation, caused by a single-base substitution of C to T, at nucleotide 2369¹⁷.

2) ALK: The rearrangement results from a short inversion in chromosome 2p, whereby *ALK* signaling is activated by the creation of oncogenic fusions of the intron 10 of *ALK* gene within an upstream partner intron 13 of echinoderm microtubule associated protein-like 4 (*EML4*)⁶. More recently, less than 1% of *ALK* rearrangements cases have different partner genes including kinesin family member 5B (*KIF5B*), *TFG*, and *KLC-1*^{11,18}. *ALK* rearrangements occur in approximately 4% of lung adenocarcinoma patients, usually young, non-smokers with clinically advanced disease⁶⁻⁸. The United States Food and Drug Administration approved the *ALK* Break Apart fluorescence *in situ* hybridization (FISH) Probe Kit (Abbott Molecular, Des Plaines, IL, USA) as a companion diagnostic for targeted therapy with crizotinib in lung cancers¹.

3) ROS1: *ROS1* is a proto-oncogene located on chromosome 6q22 that encodes a transmembrane tyrosine kinase receptor of the insulin receptor family¹⁹. *ROS1* gene rearrangements are known oncogenic drivers in NSCLC, and several fusion partners have been identified, including *CD74*, *SLC34A2/NaPi2b*, and *FIG*^{9,19}. *ROS1* fusions are present in about 2% of NSCLC cases and are often seen in young, non-smokers with adenocarcinoma, a population similar to those with *ALK*-rearranged NSCLC^{9,19}. There is *in vitro* and early clinical evidence that lung cancers with *ROS1* rearrangements are sensitive to TKIs including crizotinib^{9,11,19}.

4) RET: *RET* is a proto-oncogene located on chromosome

Table 1. A variety of genes involved in targeted treatment of non-small cell lung cancer along with their respective histologic subtypes and the method of detection^{2,8,9,11}

Gene	Frequency according to NSCLC histologic subtype		Therapeutic agent	Method of detection		
	AD	SQ		IHC	FISH	Other
<i>EGFR</i>	10–40% mutation	Rare non-canonical mutation, 7% amplification	Erlotinib, gefitinib, afatinib	±	–	+
<i>ALK</i>	4% translocation	0%	Crizotinib	+	+	+
<i>ROS1</i>	2% translocation	0%	Crizotinib	±	+	–
<i>RET</i>	2% translocation	0%	Crizotinib, sunitinib, sorafenib, vandetanib, cabozantinib	–	+	–
<i>BRAF</i>	2% mutation	0%	Vemurafenib, GSK2118436	±	–	+
<i>MET</i>	5% amplification	10% amplification	Cabozantinib, crizotinib, rilotumumab	+	+	–
<i>HER2</i>	2% mutation	<1% mutation	Trastuzumab, afatinib, dacomitinib, neratinib	–	–	+
<i>FGFR1</i>	3% amplification	21% amplification	AZD4547, brivanib, S49076, ponatinib	–	+	–
<i>PIK3CA</i>	<2% mutation	10% mutation	BKM120, GDC-0941, XL-147	–	–	+
<i>PTEN</i>	2% inactivation	10% inactivation	Vandetanib	+	–	–
<i>DDR2</i>	<1% mutation	4% mutation	Dasatinib	–	–	+

NSCLC: non-small cell lung cancer; AD: adenocarcinoma; SQ: squamous cell carcinoma; IHC: immunohistochemistry; FISH: fluorescence *in situ* hybridization; Other: other molecular methods for the detection of genetic alteration including mutation and indels.

10q11.2 that encodes a receptor tyrosine kinase involved in neural crest development²⁰. Translocations resulting in fusions with several partners have been reported in lung cancer, including multiple variants of *KIF5B-RET* (the most common type), *CCDC6-RET* (PTC1), *NCOA4-RET* (PTC3), and *TRIM33-RET*². *RET* fusions are known to occur in the young, non-smokers with adenocarcinoma, but no other driver mutations, and can be targeted with TKIs such as sunitinib, sorafenib, vandetanib, and cabozantinib^{2,9,11,20}.

5) BRAF: *BRAF* encodes a serine/threonine protein kinase that is the downstream effector protein of KRAS and activates the mitogen-activated protein kinase (MAPK) signal transduction pathway involved in the regulation of cell proliferation and survival^{11,21}. In contrast to melanoma, about 50% of the mutations are non-V600E mutations such as L596R and G468A. It is unknown whether V600E *BRAF* mutations function as driver mutations and other mutations as passenger mutations². Non-V600E mutations have been associated with current or former smokers, while V600E mutations appear to be more common in female, non-smokers^{11,21}. *BRAF*-mutated NSCLC cases have been reported to respond to vemurafenib^{2,11}.

6) MET: *MET* is a proto-oncogene located on chromosome 7q21–q31 that encodes a transmembrane tyrosine kinase receptor for its ligand hepatocyte growth factor (HGF)²². Mutations in *MET* are rare, but a high *MET* gene copy number has been detected in 1–11% of NSCLC cases. High gene copy numbers are more common in squamous cell carcinoma than adenocarcinoma and are often associated with high MET protein expression and poor prognosis^{9,11}. *MET* amplification that drives and maintains the phosphatidylinositol 3-kinases (PI3K)/AKT pathway, bypassing *EGFR* blockade by TKIs, has emerged as one of the critical events for secondary resistance to EGFR-TKIs in patients with *EGFR*-mutated lung adenocarcinoma²³. A number of therapeutic agents targeting the MET/HGF pathway are in clinical development, including cabozantinib, crizotinib, and rilotumumab (antagonistic antibodies against HGF)⁹.

7) HER2: *HER2* is member of the HER (EGFR) family of tyrosine kinase receptors. *HER2* mutations are detected mainly in exon 20 in approximately 1–2% of NSCLC cases, predominantly in adenocarcinomas in non-smoking women¹¹. *HER2*-mutated adenocarcinoma cases have been reported to respond to trastuzumab and afatinib²⁴.

8) FGFR1: *FGFR1* is a membrane-bound tyrosine-kinase receptor involved in the regulation of cell proliferation and angiogenesis through activation of the MAPK and PI3K pathways^{9,25}. *FGFR1* amplification occurs more frequently in squamous cell carcinoma (21%) than in adenocarcinoma (3%)^{9,25}. The novel FGFR inhibitor ponatinib may be effective in patients with FGFR1 overexpression and the results of ongoing trials are pending²⁵.

9) PIK3CA: PI3K protein family are intracellular lipid ki-

nases and the main catalytic subunit, the p110 α isoform, is encoded by the *PIK3CA*⁹. *PIK3CA* mutations mostly involve the catalytic domain and have been identified in approximately 1–3% of NSCLCs, particularly in squamous cell carcinomas^{9,26}. Trials with PI3K inhibitors in combination with chemotherapy and other targeted agents are ongoing.

10) PTEN: *PTEN* encodes a lipid and protein phosphatase on chromosome 10 that plays a significant role in cell cycle progression, apoptosis, growth, proliferation, and migration via negative control of the PI3K/AKT pathway²⁷. *PTEN* mutations and loss of PTEN protein expression are relatively common in squamous cell carcinoma⁹. The TKI vandetanib has shown efficacy against *EGFR* mutation-positive lung cancer cell lines showing a loss of PTEN²⁸.

11) Discoidin domain receptor 2 (DDR2): *DDR2* encodes a membrane-bound receptor tyrosine kinase that binds collagen and is involved in the regulation of cell proliferation and survival^{2,29}. Mutations of *DDR2* gene occur in 3.8% of squamous cell carcinomas and are associated with oncogenic activity that may respond to dasatinib²⁹.

2. Present strategy for molecular testing

The molecular targets as described above now define the characteristics of NSCLC. However, *EGFR* mutation testing and *ALK* rearrangement status are the only two molecular makers considered the standard-of-care of NSCLC treatment in daily practice currently. The development of new therapeutic agents has led accurate histologic subtyping and molecular predictive testing to become mandatory in NSCLC cases.

1) Histologic subtyping: Histologic subtyping is still important in triaging tumor samples for appropriate molecular testing, as pathologists become more important in the management of patients with lung cancer. It has become clinically relevant to distinguish between adenocarcinoma and squamous cell carcinoma, as the chemotherapy regimen differs for these histologic subtypes¹. Because minimally invasive procedures must be employed to obtain diagnostic material in more than 85% of NSCLC cases, an accurate but tissue-sparing approach from the limited cytology or small biopsy specimen is necessary¹. Pathologists should try to classify further poorly differentiated NSCLC with the application of a panel of immunohistochemical markers, such as thyroid transcription factor-1 and napsin A to identify an adenocarcinoma component, and p63/p40 to identify a squamous cell carcinoma component³⁰.

2) Molecular guidelines for testing of EGFR and ALK: Several guidelines for molecular testing have been published in the past couple of years^{1,31,32}. Recently, the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology guidelines provide the first standardized evidence-based approach for performing molecular testing to on select patients with lung

cancer for EGFR or ALK TKI therapy that is multidisciplinary and multicontinental in scope¹. The details have been described elsewhere. Briefly, adenocarcinoma is a basis for conducting molecular testing. Specimens from either primary or metastatic lesions are equally suitable for testing. For limited specimens, *EGFR* testing should be prioritized first and *ALK* testing should be prioritized second over other molecular markers. The guidelines encourage *EGFR* and *ALK* testing of biopsies at the time of diagnosis for patients presenting with early stage lung cancer. Alternatively, if testing is not performed in these early stage cancers, the guidelines encourage the retaining of cancer tissue for future biomarker testing. Mutation analysis, using a validated method with sufficient performance characteristics, such as direct sequencing, pyrosequencing, and peptide nucleic acid polymerase chain reaction (PCR) clamping, is recommended for *EGFR* mutation testing. A wide range of sample types, including cytology specimens and fixatives (formalin-fixed paraffin-embedded [FFPE], fresh, frozen, and alcohol) are allowable for *EGFR* mutation testing. FISH assays using dual-labeled break-apart probes are recommended for *ALK* gene rearrangement testing¹.

Future Directions

1. Future development of molecular testing

Advances in genomic technology such as NGS and multiplex PCR assays have now made it possible to analyze the genomic landscape of lung cancer tissues comprehensively. A detailed understanding of the complex genetic pathways responsible for the initiation and maintenance of malignant transformation may lead to the identification of vulnerabilities in cancers, and in turn may enable identification of novel therapeutic targets.

1) NGS: NGS offers simultaneous sequencing of thousands to millions of short nucleic acid sequences in a massively parallel way¹². These modern but costly technologies have been applied to whole genome sequencing and whole exome sequencing for the discovery of mutations and polymorphisms, transcriptome sequencing for the quantification of gene expression, small ribonucleic acid sequencing for microRNA profiling, large-scale analysis of DNA methylation, and chromatin immunoprecipitation mapping of DNA-protein interaction. NGS can detect chromosomal rearrangements and gene copy number alterations at a very high resolution³³. It can be performed on FFPE and freshly collected tissue specimens and on small fine-needle aspiration biopsies.

Moreover, targeted NGS is beginning to be implemented in clinical laboratory practice. It is applied to detect individual mutations in cancer-related genes that may assist in cancer diagnosis, have prognostic value, or be used for prediction of response to targeted therapy^{8,13}. Targeted NGS assays require

no prior knowledge of the mutations present in a patient's tumor and are not limited to an evaluation of comparatively few 'hot spots' in which specific mutations are known to occur¹³.

However, NGS is not clinically applicable as of today. The implementation of NGS technology in a clinical laboratory is complex and requires significant expertise in clinical, technical, cost-benefit, and the bioinformatics aspects of sequencing. Careful ethical consideration must also be given to the design of control arms in clinical trials of biomarker-selected patients^{8,9}.

2) Multiplex PCR: Multiple PCRs that evaluates known 'hot spot' mutations by multiplex PCR involve the simultaneous amplification of two or more cDNA/DNA targets in a single reaction vessel with uniquely labelled probes for each target³⁴. A number of multiplex PCR-based assays are available, including SNaPshot (Applied Biosystems, Foster City, CA, USA) and Sequenom MassARRAY (Sequenom Inc., San Diego, CA, USA)⁹. Multiplex PCR has been used to differentiate metastases from synchronous primary tumors in patients with multiple lung masses, and has the advantage of needing only a small sample of tumor compared with conventional tests, but it is restricted to codons previously determined as mutation hotspots, and is unable to detect chromosomal rearrangements or determine gene copy number⁹.

2. The Cancer Genome Atlas (TCGA) Project

More recently, systematic cancer genomics projects have applied emerging technologies to the analysis of specific tumor types including the TCGA project³⁵. TCGA's principal aims are to generate, quality control, merge, analyze, and interpret molecular profiles at the DNA, RNA, protein, and epigenetic levels for hundreds of clinical tumors from various tumor types and their subtypes³⁵. By the end of 2015, the TCGA Network plans to have achieved the ambitious goal of analyzing the genomic, epigenomic, and gene expression profiles of more than 10,000 specimens from 25 different tumor types including lung cancer. TCGA has already identified both common and unique mutation spectra and pathway activation in 183 lung adenocarcinomas³⁶ and 178 squamous cell carcinomas³⁷, two major histologies in NSCLC. Exonic regions of the 183 adenocarcinoma cases contained 77,736 somatic variants corresponding to a median of 8.1 mutations/megabase (MB) and a mean of 11.9 mutations/MB (range, 0.04–117.4 mutations/MB)³⁶, whereas a total of 48,690 non-silent mutations with a mean of 228 non-silent and 360 total exonic mutations per tumor, corresponding to a mean somatic mutation rate of 8.1 mutations/MB and media of 8.4/MB in squamous cell carcinoma³⁷. Those rates are higher than rates observed in other TCGA projects including acute myelogenous leukemia (0.56/MB), breast carcinoma (1.0/MB), ovarian cancer (2.1/MB), glioblastoma multiforme (2.3/MB), and colorectal carcinoma (3.2/MB).

1) Adenocarcinoma: Statistical driver analysis yielded previously reported and novel lung adenocarcinoma genes and these included lung adenocarcinoma genes with non-synonymous mutation frequencies consistent with previous reports: *TP53* (50%), *KRAS* (27%), *EGFR* (17%), *STK11* (15%), *KEAP1* (12%), *NF1* (11%), *BRAF* (8%), and *SMAD4* (3%). In total, 25 genes were shown to have a statistically significant number of mutations in lung adenocarcinoma. Unexpectedly, *U2AF1*, *RBM10*, and *ARID1A* mutations were identified. One of the most significantly mutated genes in this lung adenocarcinoma cohort was *U2AF1*, which had non-synonymous mutations in 3% of cases. *U2AF1* mutation may confer tumorigenic capability independent of known proliferations-sustaining driver genes and patients with *U2AF1* mutations had significantly reduced PFS. *RBM10*, encoding an RNA-binding protein, was mutated in 7% of cases and its mutations co-occurred with those in known lung adenocarcinoma oncogenes. *ARID1A*, encoding a key protein in the SW1/SNF chromatin-remodeling complex, was mutated in 8% of cases and showed a significant accumulation of nonsense substitutions and frameshift indels³⁶.

2) Squamous cell carcinoma: Lung squamous cell carcinoma is characterized by complex genomic alterations. In total, 18 genes were shown to have a statistically significant number of mutations including mutation of *TP53* in nearly all specimens. Significantly altered pathways by mutation or somatic copy number alterations included *NFE2L2/KEAP1* in 34%, *SOX2/TP63/NOTCH1* pathways in 44%, one of three components of the PI3K/AKT pathway (*PIK3CA*, *PTEN* or *AKT3*) in 47%, and *CDKN2A* (a known tumor suppressor gene that encodes the INK4A/p16 and ARF/p14 proteins)/*RB1* in 72% of cases, providing evidence of common dysfunction in response to oxidative stress, squamous cell differentiation, apoptotic signaling, and/or cell cycle control, respectively. Previously unreported loss-of-function mutations were seen in the *HLA-A* class I major histocompatibility gene, suggesting a possible role for genotypic selection of patients for immunotherapies. Lung squamous cell carcinomas also share many alterations in common with head and neck squamous cell carcinomas without evidence of human papillomavirus infection, suggesting that the biology of these two diseases may be similar³⁷.

Conclusion

In light of the myriad new biomarkers and targeted agents, multiplex testing strategies will be invaluable in identifying the appropriate patients for each therapy and enabling targeted agents to be channeled to the patients most likely to gain benefit. As further studies with sensitive multigene assays are completed, one might expect that the data will provide a key comprehensive means of identifying somatic alterations in

entire lung cancer genomes or exomes and will ultimately inform clinical decision-making.

Conflicts of Interest

No potential conflict of interest relevant to this article was reported.

Acknowledgements

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (Ministry of Science, ICT & Future Planning) [grant number: 2013R1A1A3007362].

References

- Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. *J Thorac Oncol* 2013;8: 823-59.
- Thunnissen E, van der Oord K, den Bakker M. Prognostic and predictive biomarkers in lung cancer. A review. *Virchows Arch* 2014;464:347-58.
- Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med* 2004;350: 2129-39.
- Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med* 2009;361:947-57.
- Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with *EGFR* mutations. *J Clin Oncol* 2013;31:3327-34.
- Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. *Nature* 2007;448:561-6.
- Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. *N Engl J Med* 2013;368:2385-94.
- Dacic S, Nikiforova MN. Present and future molecular testing of lung carcinoma. *Adv Anat Pathol* 2014;21:94-9.
- Shames DS, Wistuba II. The evolving genomic classification of lung cancer. *J Pathol* 2014;232:121-33.

10. Cagle PT, Allen TC, Olsen RJ. Lung cancer biomarkers: present status and future developments. *Arch Pathol Lab Med* 2013;137:1191-8.
11. Cooper WA, Lam DC, O'Toole SA, Minna JD. Molecular biology of lung cancer. *J Thorac Dis* 2013;5 Suppl 5:S479-90.
12. Bentley DR, Balasubramanian S, Swerdlow HP, Smith GP, Milton J, Brown CG, et al. Accurate whole human genome sequencing using reversible terminator chemistry. *Nature* 2008;456:53-9.
13. Summerer D. Enabling technologies of genomic-scale sequence enrichment for targeted high-throughput sequencing. *Genomics* 2009;94:363-8.
14. Glenn TC. Field guide to next-generation DNA sequencers. *Mol Ecol Resour* 2011;11:759-69.
15. Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. *Endocr Relat Cancer* 2001;8:11-31.
16. Dearden S, Stevens J, Wu YL, Blowers D. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). *Ann Oncol* 2013;24:2371-6.
17. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. *PLoS Med* 2005;2:e73.
18. Takeuchi K, Choi YL, Togashi Y, Soda M, Hatano S, Inamura K, et al. KIF5B-ALK, a novel fusion oncokine identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. *Clin Cancer Res* 2009;15:3143-9.
19. Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, et al. *ROS1* rearrangements define a unique molecular class of lung cancers. *J Clin Oncol* 2012;30:863-70.
20. Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M, Nammo T, et al. *KIF5B-RET* fusions in lung adenocarcinoma. *Nat Med* 2012;18:375-7.
21. Marchetti A, Felicioni L, Malatesta S, Grazia Sciarrotta M, Guetti L, Chella A, et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. *J Clin Oncol* 2011;29:3574-9.
22. Sadiq AA, Salgia R. MET as a possible target for non-small-cell lung cancer. *J Clin Oncol* 2013;31:1089-96.
23. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. *MET* amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. *Science* 2007;316:1039-43.
24. Mazieres J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, et al. Lung cancer that harbors an *HER2* mutation: epidemiologic characteristics and therapeutic perspectives. *J Clin Oncol* 2013;31:1997-2003.
25. Dutt A, Ramos AH, Hammerman PS, Mermel C, Cho J, Sharifnia T, et al. Inhibitor-sensitive *FGFR1* amplification in human non-small cell lung cancer. *PLoS One* 2011;6:e20351.
26. Spoerke JM, O'Brien C, Huw L, Koeppen H, Fridlyand J, Brachmann RK, et al. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models. *Clin Cancer Res* 2012;18:6771-83.
27. Abdulkareem IH, Blair M. Phosphatase and tensin homologue deleted on chromosome 10. *Niger Med J* 2013;54:79-86.
28. Takeda H, Takigawa N, Ohashi K, Minami D, Kataoka I, Ichihara E, et al. Vandetanib is effective in *EGFR*-mutant lung cancer cells with PTEN deficiency. *Exp Cell Res* 2013;319:417-23.
29. Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W, et al. Mutations in the *DDR2* kinase gene identify a novel therapeutic target in squamous cell lung cancer. *Cancer Discov* 2011;1:78-89.
30. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. *J Thorac Oncol* 2011;6:244-85.
31. Shim HS, Chung JH, Kim L, Chang S, Kim WS, Lee GK, et al. Guideline recommendations for *EGFR* mutation testing in lung cancer: proposal of the Korean Cardiopulmonary Pathology Study Group. *Korean J Pathol* 2013;47:100-6.
32. Kim H, Shim HS, Kim L, Kim TJ, Kwon KY, Lee GK, et al. Guideline recommendations for testing of *ALK* gene rearrangement in lung cancer: a proposal of the Korean Cardiopulmonary Pathology Study Group. *Korean J Pathol* 2014;48:1-9.
33. Thomas A, Rajan A, Lopez-Chavez A, Wang Y, Giaccone G. From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma. *Ann Oncol* 2013;24:577-85.
34. Persson K, Hamby K, Ugozzoli LA. Four-color multiplex reverse transcription polymerase chain reaction--overcoming its limitations. *Anal Biochem* 2005;344:33-42.
35. Cancer Genome Atlas Research Network, Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, et al. The Cancer Genome Atlas Pan-Cancer analysis project. *Nat Genet* 2013;45:1113-20.
36. Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. *Cell* 2012;150:1107-20.
37. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. *Nature* 2012;489:519-25.